MannKind (MNKD) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Q1 2026 earnings due May 6: MannKind is expected to report results before market open on Wednesday, May 6, with analysts forecasting EPS of ($0.02) and revenue of $105.38 million (earnings call listed at 4:30 PM ET).
• Mixed recent results but strong revenue growth: In the prior quarter MannKind missed EPS expectations (‑$0.05 vs. consensus ‑$0.01) but reported $111.96 million in revenue, up 45.8% year‑over‑year; the stock carries an average analyst rating of "Moderate Buy" and a $8.69 average price target.
• Insider buying and institutional interest: CEO Michael Castagna purchased 100,000 shares at $2.59, raising his stake to 2,575,911 shares; insiders own 2.60% of the company while institutional investors hold roughly 49.55%.

MannKind (NASDAQ:MNKD - Get Free Report) will likely be issuing its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $105.3810 million for the quarter. Parties may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.

MannKind (NASDAQ:MNKD - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.04). MannKind had a net margin of 1.68% and a negative return on equity of 11.21%. The company had revenue of $111.96 million for the quarter, compared to the consensus estimate of $99.85 million. During the same quarter in the prior year, the company earned $0.03 earnings per share. The company's quarterly revenue was up 45.8% on a year-over-year basis. On average, analysts expect MannKind to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MannKind Stock Up 0.4%

Shares of MNKD opened at $2.84 on Friday. The business's 50-day moving average price is $2.86 and its 200-day moving average price is $4.64. MannKind has a twelve month low of $2.23 and a twelve month high of $6.51. The stock has a market cap of $876.99 million, a PE ratio of 142.07 and a beta of 1.04.

Wall Street Analyst Weigh In

MNKD has been the topic of several analyst reports. Zacks Research upgraded MannKind from a "strong sell" rating to a "hold" rating in a research report on Wednesday, April 15th. Wells Fargo & Company upped their price target on MannKind from $7.00 to $8.00 and gave the company an "overweight" rating in a research report on Tuesday. HC Wainwright reiterated a "buy" rating and set a $11.00 price target on shares of MannKind in a research report on Wednesday, February 25th. Wall Street Zen cut MannKind from a "buy" rating to a "hold" rating in a research report on Saturday, February 28th. Finally, Royal Bank Of Canada reiterated a "sector perform" rating and set a $3.50 price target (down from $7.50) on shares of MannKind in a research report on Friday, February 27th. Seven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $8.69.

Insider Buying and Selling at MannKind

In related news, CEO Michael Castagna acquired 100,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 10th. The shares were bought at an average cost of $2.59 per share, for a total transaction of $259,000.00. Following the completion of the transaction, the chief executive officer owned 2,575,911 shares in the company, valued at approximately $6,671,609.49. This trade represents a 4.04% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 2.60% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Mercer Global Advisors Inc. ADV bought a new position in shares of MannKind in the fourth quarter worth approximately $70,000. Voloridge Investment Management LLC increased its position in shares of MannKind by 50.8% in the fourth quarter. Voloridge Investment Management LLC now owns 1,861,046 shares of the biopharmaceutical company's stock worth $10,552,000 after purchasing an additional 626,878 shares during the last quarter. Tudor Investment Corp ET AL bought a new position in shares of MannKind in the fourth quarter worth approximately $182,000. Polymer Capital Management US LLC bought a new position in shares of MannKind in the fourth quarter worth approximately $168,000. Finally, Man Group plc boosted its stake in MannKind by 80.9% in the fourth quarter. Man Group plc now owns 178,494 shares of the biopharmaceutical company's stock worth $1,012,000 after buying an additional 79,843 shares in the last quarter. 49.55% of the stock is currently owned by institutional investors.

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company's core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind's lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.